Lv32
280 积分 2025-12-12 加入
Estimation and application of the minimum clinically important difference in COPD
5天前
已完结
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
1个月前
已完结
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
1个月前
已完结
A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52)
1个月前
已完结
A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis
1个月前
已完结
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
1个月前
已完结
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study
2个月前
已完结
Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis
2个月前
已完结
皖公网安备34019202002308
